Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging

Insulinoma is one of the most common pancreatic endocrine neoplasm and is difficult to be detected by typical technology. Radionuclide imaging methods such as SPECT and PET have provided a new technology for insulinoma diagnosis with advantages of non-invasive, high sensitivity and specificity. Glucagon-like peptide-1 receptor(GLP-1R) is an attractive target for imaging due to its overexpression in insulinoma. Exendin-4, the agonist of GLP-1R, could specifically bind to the receptor. This paper reviews the progress of radionuclide-labeled Exendin-4 analogs in insulinoma imaging.